Differential expression of microRNA and predicted targets in pulmonary sarcoidosis

Crouser, Elliott D.; Julián, M; Crawford, Melissa; Shao, Guohong; Yu, Lianbo; Planck, Stephen R.; Rosenbaum, James T.; Nana‐Sinkam, S. Patrick

doi:10.1016/j.bbrc.2011.12.068

Cited by 44 publications

(64 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In pulmonary sarcoidosis, the intracellular expression of miRNAs has been investigated in bronchoalveolar cells, peripheral blood mononuclear cells, and the lung tissue [4–6]. In addition, some intracellular miRNAs have been reported to have altered expression during sarcoidosis progression [4, 5].…”

Section: Introductionmentioning

confidence: 99%

The Serum Expression of Selected miRNAs in Pulmonary Sarcoidosis with/without Löfgren’s Syndrome

Novosadová

Chabronova

Kolek

et al. 2016

Mediators of Inflammation

View full text Add to dashboard Cite

Purpose. Pulmonary sarcoidosis is associated with dysregulated expression of intracellular miRNAs. There is however only little information on extracellular miRNAs and their association with the disease course in sarcoidosis. We therefore assessed serum miRNAs in sarcoidosis classified according to the presence of Löfgren's syndrome (LS) as a hallmark of good prognosis in contrast to more advanced disease course. Methods. RT-PCR was used to assess 35 miRNAs in 13 healthy controls and 24 sarcoidosis patients (12 with X-ray (CXR) stage ≤ 1 and LS and 12 with insidious onset and CXR stage ≥ 3). Results. Compared to controls, we consistently observed dysregulated expressions of miR-146, miR-16, miR-425-5p, and miR-93-5p in both sarcoidosis groups irrespective of disease course. Specifically, patients without LS had dysregulated expressions of miR-150-5p, miR-1, and miR-212 compared to controls. Patients with LS had dysregulated expressions of miR-21-5p and miR-340-5p compared to controls. Bioinformatics predicted consistently “Pathways in cancer” to be modulated by both altered profiles in patients with/without LS. Three miRNAs (miR-21-5p, miR-340-5p, and miR-212-3p) differed between our patients with LS and those without LS; their cumulative effect may modulate “TGF-β signalling pathway.” Conclusions. Further study should focus on possible applications of serum miRNAs for diagnostics follow-up and for prognosis.

show abstract

Section: Introductionmentioning

confidence: 99%

The Serum Expression of Selected miRNAs in Pulmonary Sarcoidosis with/without Löfgren’s Syndrome

Novosadová

Chabronova

Kolek

et al. 2016

Mediators of Inflammation

View full text Add to dashboard Cite

show abstract

“…Several groups, including ours, 7 have used this type of analysis of messenger RNA transcripts to study sarcoidosis in sites, including the lungs, 8–10 lymph nodes, 11 peripheral blood, 12–15 heart, 16 and skin. 17 …”

mentioning

confidence: 99%

Parallel Gene Expression Changes in Sarcoidosis Involving the Lacrimal Gland, Orbital Tissue, or Blood

et al. 2015

Self Cite

View full text Add to dashboard Cite

IMPORTANCE Sarcoidosis is a major cause of ocular or periocular inflammation. The pathogenesis of sarcoidosis is incompletely understood and diagnosis often requires a biopsy.OBJECTIVE To determine how gene expression in either orbital adipose tissue or the lacrimal gland affected by sarcoidosis compares with gene expression in other causes of orbital disease and how gene expression in tissue affected by sarcoidosis compares with gene expression in peripheral blood samples obtained from patients with sarcoidosis. DESIGN, SETTING, AND PARTICIPANTSIn a multicenter, international, observational study, gene expression profiling of formalin-fixed biopsy specimens, using GeneChipp U133 Plus 2 microarrays (Affymetrix), was conducted between October 2012 and January 2014 on tissues biopsied from January 2000 through June 2013. Participants included 12 patients with orbital sarcoidosis (7 in adipose tissue; 5 affecting the lacrimal gland) as well as comparable tissue from 6 healthy individuals serving as controls or patients with thyroid eye disease, nonspecific orbital inflammation, or granulomatosis with polyangiitis. In addition, results were compared with gene expression in peripheral blood samples obtained from 12 historical individuals with sarcoidosis. MAIN OUTCOMES AND MEASURESSignificantly differentially expressed transcripts defined as a minimum of a 1.5-fold increase or a comparable decrease and a false discovery rate of P < .05.RESULTS Signals from 2449 probe sets (transcripts from approximately 1522 genes) were significantly increased in the orbital adipose tissue from patients with sarcoidosis. Signals from 4050 probe sets (approximately 2619 genes) were significantly decreased. Signals from 3069 probe sets (approximately 2001 genes) were significantly higher and 3320 (approximately 2283 genes) were significantly lower in the lacrimal gland for patients with sarcoidosis. Ninety-two probe sets (approximately 69 genes) had significantly elevated signals and 67 probe sets (approximately 56 genes) had significantly lower signals in both orbital tissues and in peripheral blood from patients with sarcoidosis. The transcription factors, interferon-response factor 1, interferon-response factor 2, and nuclear factor κB, were strongly implicated in the expression of messenger RNA upregulated in common in the 3 tissues.CONCLUSIONS AND RELEVANCE Gene expression in sarcoidosis involving the orbit or lacrimal gland can be distinguished from gene expression patterns in control tissue and overlaps with many transcripts upregulated or downregulated in the peripheral blood of patients with sarcoidosis. These observations suggest that common pathogenic mechanisms contribute to sarcoidosis in different sites. The observations support the hypothesis that a pattern of gene expression profiles could provide diagnostic information in patients with sarcoidosis.

show abstract

“…In particular, in sarcoidosis patients, miR-144 is largely upregulated in blood, and miR-20a and miR-302c are decreased in lung, but elevated in lymph node tissues, whereas the expression of miR-92b and miR-206 is elevated in both lung and lymph node tissues [200,201]. Recently, Jazwa and co-workers detected an upregulation of miRNA in PBMC from sarcoidosis patients [202].…”

Section: Micrornasmentioning

confidence: 97%

“…SSc, IPF FBs, Serum, Lung, Mouse Lung [194,305] miR-154 IPF Lung [192] miR-375 IPF Rat Lung [193] miR-92-a-b SSc, Sarcoidosis FBs, Serum, PBMC, Lung [200,201,306] miR-142 SSc Serum [307] miR-150 SSc FBs, Serum [308] miR-196a SSc FBs, Serum, and Hair Shafts [309,310] miR-128 IPF Lung [184] miR-200 IPF Lung FBs, Mouse Lung [195] miR-338 IPF Rat Lung FBs [199] miR-17-92 cluster IPF Lung, Mouse Lung [196] miR-34-a Sarcoidosis PBMC [202] miR-25 Sarcoidosis PBMC [200] miR-199a-5P Sarcoidosis, IPF PBMC, Mouse [200] mir-214 Sarcoidosis PBMC [200] miR-144 Sarcoidosis PBMC [200,201] mir-302c Sarcoidosis PBMC [200,201] mir-206 Sarcoidosis PBMC [200,201] miR-20-a Sarcoidosis PBMC [200,201] lncRNA MRAK088388 IPF Mouse [204] lncRNA MRAK081523 IPF Mouse [204] FBs: Fibroblasts; PBMC: Peripheral blood mononucleated cells. trans-differentiation by targeting Frizzled, a trans-membrane receptor of Wnt ligands [193].…”

Section: Micrornasmentioning

confidence: 99%

Facts and promises on lung biomarkers in interstitial lung diseases

Campo

Zorzetto

Bonella

2015

Expert Review of Respiratory Medicine

View full text Add to dashboard Cite

Interstitial lung diseases (ILDs) are a heterogeneous group of >100 pulmonary disorders. ILDs are characterized by an irreversible architectural distortion and impaired gas exchange; however, there is great variability in the clinical course. ILD diagnosis requires a combination of clinical data, radiological imaging and histological findings (when a lung biopsy is required). At the same time, successful management of ILD patients strictly depends on an accurate and confident diagnosis. In this context, the detection of reliable biomarkers able to identify ILD subtypes, avoiding lung biopsy, as well as the capacity to stratify patients and predict over time the disease course, has become a primary aim for all research studies in this field.

show abstract

Differential expression of microRNA and predicted targets in pulmonary sarcoidosis

Cited by 44 publications

References 46 publications

The Serum Expression of Selected miRNAs in Pulmonary Sarcoidosis with/without Löfgren’s Syndrome

The Serum Expression of Selected miRNAs in Pulmonary Sarcoidosis with/without Löfgren’s Syndrome

Parallel Gene Expression Changes in Sarcoidosis Involving the Lacrimal Gland, Orbital Tissue, or Blood

Facts and promises on lung biomarkers in interstitial lung diseases

Contact Info

Product

Resources

About